Less-invasive fascia-preserving surgery for abdominal wall desmoid

Yoshihiro Nishida1,3,*, Shunsuke Hamada2, Tomohisa Sakai3, Kan Ito3, Kunihiro Ikuta3, Hiroshi Urakawa3, Hiroshi Koike3 & Shiro Imagama3

The mainstay of treatment for desmoid has been shifted to active surveillance (AS). However, surgery is still being performed on abdominal wall desmoid with a wide surgical margin. The purposes of this study are to clarify the treatment results of less-invasive, fascia preserving surgery for patients with abdominal wall desmoid, and to propose a new treatment modality. Since 2009, 34 patients with abdominal desmoid have been treated in our institution. Among them, as a final treatment modality, 15 (44%) were successful with AS, 15 were subjected to less-invasive surgery, and 4 methotrexate and vinblastine treatment. The clinical results of less-invasive surgery were clarified. In the surgical group, although the surgical margin was all microscopic positive (R1), only one patient (6.7%), who has the S45F mutation type of CTNNB1, showed recurrence, at a mean follow-up of 45 months. There were no patients with familial adenomatous polyposis (FAP)-related desmoid in this cohort. Only two patients (13%) required fascia lata patch reconstruction after removal of the tumor. In patients with non-FAP-related abdominal wall desmoid, less-invasive, fascia preserving surgery is recommended as a favorable option as active treatment. Based on the results of this study, multi-institutional further research is warranted with an increased number of patients.

Desmoid-type fibromatosis (desmoid) is a proliferative disease of (myo)fibroblast-like cells that is classified as an intermediate tumor according to the World Health Organization classification. It tends to infiltrate surrounding tissues, but does not metastasize12.

The recurrence rate, after high quality surgery aiming for a negative surgical margin, was reported in the range of 20 to 60% in the past reports from overseas3–5, and the recurrence rate has been reported to be similar in Japanese6,7. The recurrence rate has also been found to be higher in children and adolescents8.

For these reasons, the treatment modality for desmoid has changed in recent years, and the policy is to first follow up with active surveillance (AS) without performing surgery9,10. However, when the AS policy fails, it is necessary to consider active treatment. Regarding surgical treatment, postoperative results differ greatly depending on the site of occurrence, and it has been reported that the recurrence rate is particularly low for abdominal wall desmoids11–13. A consensus paper based on a review of these pieces of evidence has provided a treatment algorithm including surgical options after AS for abdominal wall desmoid, which is different from those in other locations9.

Regarding the relationship between surgical margin and postoperative recurrence for desmoid, an increasing number of research reports have indicated that there is no association between resection margins (R0 vs R1) and recurrence rates3,5,7,11,13,14. If there is no difference in the results between the method of removing only the macroscopic tumor and microscopic negative margin surgery for abdominal wall desmoid, non-invasive surgery has advantages for patients.

However, in the previous reports of surgery for abdominal wall desmoid aiming at a negative surgical margin, there were disadvantages to patients, such as abdominal wall defects caused by surgery and the need for mesh reconstruction15,16 or plastic surgery reconstruction17.

We have reported favorable results of surgery even with microscopic positive margin for patients with truncal desmoid including six patients with abdominal wall desmoid18. However, this report did not include patients with results based on the AS policy, or detailed surgical data (surgery time, bleeding volume, postoperative reconstruction).

1Department of Rehabilitation Medicine, Nagoya University Hospital, 65 Tsurumai, Showa, Nagoya, Aichi 466-8550, Japan. 2Department of Orthopaedic Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan. 3Department of Orthopaedic Surgery, Nagoya University Hospital, 65-Tsurumai, Showa-ku, Nagoya 466-8550, Japan. 4Email: ynishida@med.nagoya-u.ac.jp
The purpose of this study is to evaluate the treatment results of the less-invasive, fascia-preserving surgery that we have prospectively performed for patients with abdominal wall desmoid. In particular, we analyzed the recurrence rate after surgery with R1 surgical margin, the necessity of reconstruction, and the involvement of CTNNB1 mutation. In addition, we would like to clarify the significance of this surgical procedure in the treatment strategy for abdominal wall desmoid where AS becomes the mainstream.

Materials and methods
According to the medical records, between June 1991 and October 2020, 224 patients were diagnosed with desmoid and treated at our institution, of which 44 (19.6%) developed on the abdominal wall. Since 2003, the treatment modality for abdominal wall desmoid at our institution recommends non-surgical treatment initially with administration of the selective COX-2 inhibitor meloxicam19,20, but since July 2017, AS without NSAIDs including COX-2 inhibitor has been employed as the initial treatment policy, which is in accordance with the present consensus guideline9. For patients with growing tumors of the abdominal wall and/or impaired ADL/QOL such as severe pain, surgical treatment with R1 resection has been recommended to patients18 since January 2009. For patients who refuse surgical treatment, we recommend MTX and VBL treatment as another option with evidence of efficacy21–23. Except for abdominal wall development, if the tumor size increases according to the AS policy, and the ADL/QOL disorder worsens, surgery is not recommended, but MTX + VBL or pazopanib treatment is recommended. Of 44 patients with abdominal wall desmoid, after excluding 5 before 2009 when R1 resection was started, 2 who visited our outpatient clinic for a second opinion, 2 with follow-up of less than 6 months, and one who underwent surgery at another hospital, 34 patients were included in this study (Fig. 1).

Four patients refused surgical treatment when the tumor size increased, and so received MTX + VBL treatment. According to the consensus paper on desmoid treatment, no report has documented a high level of evidence regarding the effect of NSAID treatment9. Therefore, patients treated with meloxicam were included in the AS group in the present study. Abdominal wall desmoid was defined as development from the rectus abdominis muscle, oblique muscle, or transverse abdominal muscle.

AS at our institution is evaluated by MRI or CT once every three months. If the condition settles down, this is done once every 6 months.

Indications for surgery were decided in consultation with patients by explaining the outline of surgery, predicted recurrence rate, length of hospital stay etc. when the tumor size increases or symptoms such as pain worsen.

A hotspot mutation in the β-catenin gene, CTNNB1, is known to be the cause of the onset of desmoid, with the results of surgical treatment differing depending on this mutation type6,24–26. At our institution, once the pathological diagnosis of desmoid is made, the mutation type of CTNNB1 is analyzed by the Sanger method in all patients19.

Our surgical procedure for abdominal wall desmoid is different from surgery with a marginal margin. Unlike the excision in the reaction layer on the margin of the tumor, the tumor is macroscopically exposed, and detached from the fascia and muscle, and the fascia is preserved as much as possible. This makes it occasionally difficult to control bleeding from the tumor surface. On the other hand, since the fascial defect is minimal after tumor resection, wounds can be generally closed without reconstruction, such as mesh (Fig. 2).

We analyzed various clinical factors, CTNNB1 mutation status and oncological outcome in the group of less-invasive surgery. We also compared the differences in various factors between the surgery group, AS group, and MTX + VBL treatment group. Radiological response of AS or MTX + VBL treatment was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1)27. In the case of surgery, if there was no
recurrence, it was evaluated as CR, and if it recurred, it was evaluated as stable disease (SD), partial remission (PR), or progressive disease (PD) according to the change in size. This study was approved by the ethics committee of our institution (registration number: 2014–0217), and undertaken under the provisions of the Declaration of Helsinki. All of the participating patients signed informed consent forms.

Statistical analysis. Comparisons between groups were performed on categorical variables using the chi-square test or Fisher’s exact test. The Shapiro–Wilk test was performed to test the normality of the data. The Wilcoxon signed rank test was used for nonparametric analysis between the two corresponding groups. The t-test or one-way analysis of variance was used for the comparison of means in parametric data between two or more groups. Kruskal–Wallis test was used for comparison of median in nonparametric data between the three groups. LRFS was estimated using the Kaplan–Meier method. All statistical analysis was performed using SPSS version 20. P < 0.05 was considered statistically significant.

Institutional review board statement. This study was approved by Institutional Review Board of Nagoya University Hospital.

Informed consent statement. Informed consent was obtained from all subjects involved in the study.

Results
Of the 34 patients, 31 were women, the mean age at the first visit was 36 years (range: 19–68), and the median maximum tumor size at the first visit was 74 mm (range: 31–223). Patients with familial adenomatous polyposis (FAP)-related desmoid were not included.

The initial treatment modality was AS in 26 patients, and surgery was performed in 8 patients. In these 8 patients, AS was performed at other universities or specialized facilities for bone and soft tissue sarcoma. When the tumor size increased significantly and/or the activities of daily living (ADL)/quality of life (QOL) disorder became worse, they were referred to our hospital. Therefore, there were 8 patients who underwent surgery at our
institution without a period of AS. This seems to be the cause of the selection bias between the surgery group and the AS group in our institution.

Of the 26 patients with AS, eleven had tumor growth or worsening symptoms. Tumor growth was evaluated as PD by RECIST without setting an observation period. As a criterion for changing to active treatment, it was not decided by the evaluation of pain by the numerical rating scale. Instead, when the patient complained of ADL impairment due to pain, changes to active treatment were considered. Among them, seven patients underwent surgery and 4 patients were subjected to methotrexate (MTX) + vinblastine (VBL) treatment. Therefore, finally, impairment due to pain, changes to active treatment were considered. Among them, seven patients underwent surgery and 4 patients were subjected to methotrexate (MTX) + vinblastine (VBL) treatment. As a criterion for changing to active treatment, it was decided by the numerical rating scale. Instead, when the patient complained of ADL impairment due to pain, changes to active treatment were considered. Among them, seven patients underwent surgery and 4 patients were subjected to methotrexate (MTX) + vinblastine (VBL) treatment. Therefore, finally, surgical treatment was performed in 15 patients (44%), only AS policy in 15 patients (44%), and MTX + VBL in 4 patients (12%) (Fig. 1).

Of the 15 patients with surgical treatment, 14 were female, 12 patients (80%) had pain at the first visit, the mean age at the time of surgery was 36 years (range: 20–52), and the median maximum tumor diameter at the time of surgery was 11.6 cm (range: 4.5–22.3). The CTNNB1 mutation types were T41A in 6 patients, T41I in 3 patients, S45F in 1 patient, H36P in 1 patient, p.Ser45_Gly48del in 1 patient, and wild type (WT) in 3 patients. The mean and median postoperative follow-up period for patients with surgery was 45 and 38 months, respectively. Only one patient (6.7%) developed a recurrence 16 months after surgery, and interestingly it was the only patient harboring S45F mutation. In this patient, the tumor size was stable after recurrence, and then spontaneously regressed. Five-year local recurrence-free survival (LRFS) rate was 92.3%, and estimated LRFS rate was 92.3%, and estimated LRFS time was 80.6 months ± 5.2 months (confidence interval 70.5–90.8). Detailed information of patients with surgical treatment is provided in Table 1. No patients had any serious postoperative complications including hernia, and preoperative pain disappeared. No patients complained of postoperative pain because they did not require the use of mesh for reconstruction, and no ADL / QOL issues were noted.

Of the 15 patients whose progress was monitored only by AS, 7 were evaluated as complete remission (CR) (Table 2). Table 3 shows a comparison of the 15 patients with AS, 15 with fascia-preserving surgery, and 4 with MTX + VBL treatment (comparison between 3 groups). The tumor size was significantly different (p = 0.038). This was the salient difference between the surgery (11.6 cm) and AS (6.2 cm) groups in multiple comparisons using Tukey's test. There were significantly more disease-free patients in the surgery group regarding the final oncological status (p = 0.025).

Next, we focused on and analyzed the 26 patients who selected AS for the initial treatment strategy (Suppl. Table 1). Fifteen patients (58%) were able to continue AS, 7 patients (27%) switched to surgery and 4 patients (15%) switched to MTX + VBL treatment because of tumor growth and/or worsening pain. The median age was 36 years for AS, 32 years for surgery, and 29.5 years for MTX + VBL, which were lower than in the group selected for active treatment, but not significantly different (p = 0.184). The median tumor size at the first visit was AS 6.2 cm, surgery 7.3 cm, and MTX + VBL 9.1 cm (p = 0.13). In the patients switched to surgery, the tumors had increased in size significantly at the time of surgery (10.2 cm) compared to that at the first visit (7.3 cm) (p = 0.028, *P < 0.05).
In the MTX + VBL group, the tumor tended to grow from the first visit (9.1 cm) to the start of treatment (11.1 cm) ($p = 0.068$).

**Discussion**

In desmoid including abdominal development, it is recommended to follow the course with AS as much as possible$^{9,10}$. On the other hand, a systematic review of studies analyzing AS revealed that the median reported percentage of shifting to an active treatment was 29% during the course of AS. As for active treatment, it is reported that systemic treatment was the most common, followed by surgery$^{28}$. In the present study, of the 34 patients studied, all patients were treated with initial AS in pre-referral hospital or our institution. Fifteen of 34 (44%) was successful with AS. After failure of AS, the present study indicated that less invasive surgery is a good option for abdominal wall desmoid.

| Age | Gender | Size 1 | Size 2 | Pain | CTNNB1 | Treatment | F/U | RECIST |
|-----|--------|--------|--------|------|--------|-----------|-----|--------|
| 36  | F      | 6.9    | 0      | +    | WT     | +         | 117 | CR     |
| 35  | F      | 6.2    | 0      | +    | WT     | +         | 46  | CR     |
| 36  | F      | 13.5   | 0      | +    | T41A   | +         | 80  | CR     |
| 65  | M      | 8.1    | 8.5    | +    | T41A   | +         | 39  | SD     |
| 38  | F      | 6.5    | 7.7    | −    | T41A   | +         | 20  | SD     |
| 33  | F      | 5.8    | 4.2    | +    | S45F   | +         | 10  | PR     |
| 35  | F      | 6.0    | 0      | −    | NA     | +         | 41  | CR     |
| 68  | M      | 5.5    | 0      | −    | WT     | +         | 43  | CR     |
| 35  | F      | 3.6    | 0      | +    | T41I   | −         | 39  | CR     |
| 37  | F      | 3.1    | 0      | +    | NA     | +         | 31  | CR     |
| 37  | F      | 9.3    | 9.5    | +    | T41A   | +         | 25  | SD     |
| 22  | F      | 8.5    | 8.7    | +    | T41A   | −         | 20  | SD     |
| 30  | F      | 4.2    | 4.0    | +    | T41A   | −         | 9   | SD     |
| 39  | F      | 7.5    | 7.2    | +    | WT     | −         | 12  | SD     |
| 30  | F      | 6.1    | 6.1    | −    | T41A   | −         | 6   | SD     |

Table 2. Patients with treatment of only active surveillance. Age at first visit to our hospital, Size 1 maximum tumor diameter at first visit (cm), Size 2 maximum tumor diameter at last visit (cm), Treatment meloxicam or celecoxib treatment at pre-referral or our hospital, F/U follow up duration (months), RECIST evaluation between first and last visit, NA not available due to the poor quality of DNA from desmoid (pre-referral hospital), CR complete remission, PR partial remission, SD stable disease.

| Age | Gender | Size 1 | Size 2 | Pain | CTNNB1 | Treatment | F/U | RECIST |
|-----|--------|--------|--------|------|--------|-----------|-----|--------|
| 36  | F      | 6.9    | 0      | +    | WT     | +         | 117 | CR     |
| 35  | F      | 6.2    | 0      | +    | WT     | +         | 46  | CR     |
| 36  | F      | 13.5   | 0      | +    | T41A   | +         | 80  | CR     |
| 65  | M      | 8.1    | 8.5    | +    | T41A   | +         | 39  | SD     |
| 38  | F      | 6.5    | 7.7    | −    | T41A   | +         | 20  | SD     |
| 33  | F      | 5.8    | 4.2    | +    | S45F   | +         | 10  | PR     |
| 35  | F      | 6.0    | 0      | −    | NA     | +         | 41  | CR     |
| 68  | M      | 5.5    | 0      | −    | WT     | +         | 43  | CR     |
| 35  | F      | 3.6    | 0      | +    | T41I   | −         | 39  | CR     |
| 37  | F      | 3.1    | 0      | +    | NA     | +         | 31  | CR     |
| 37  | F      | 9.3    | 9.5    | +    | T41A   | +         | 25  | SD     |
| 22  | F      | 8.5    | 8.7    | +    | T41A   | −         | 20  | SD     |
| 30  | F      | 4.2    | 4.0    | +    | T41A   | −         | 9   | SD     |
| 39  | F      | 7.5    | 7.2    | +    | WT     | −         | 12  | SD     |
| 30  | F      | 6.1    | 6.1    | −    | T41A   | −         | 6   | SD     |

Table 3. Comparison between active surveillance only, surgery, and MTX + VBL treatment group. Age, size, F/U median value, MTX methotrexate, VBL vinblastine, WT wild type, F/U median follow up, duration from first visit to last visit, CR complete remission, PR partial remission, SD stable disease, PD progressive disease. *2 cases were excluded due to the low quality of DNA.

Wilcoxon signed rank test). In the MTX + VBL group, the tumor tended to grow from the first visit (9.1 cm) to the start of treatment (11.1 cm) ($p = 0.068$).
The present study revealed that the recurrence rate of abdominal wall desmoid is very low (6.7%) even with less-invasive, fascia-preserving surgery. Table 4 summarizes 6 past reports and the present study on the surgical results of abdominal wall desmoid. The recurrence rate noted in each of these reports was very good, from 0 to 16%, and the total recurrence rate of the past 6 reports was 6.2% (9/145). Bonvalot et al. reported that 18 of 41 patients had a surgical margin of R1, despite which only 1 patient showed recurrence. Of the 145 patients, R0 or wide resection was performed in 96 (66%) with a recurrence rate of 6.2%. It is very interesting that the recurrence rate (6.7%) of the present study, which was all R1 surgery, was equivalent, suggesting the importance of less-invasive surgery compared to surgery with a wide surgical margin. According to a report from a multicenter joint study from Japan, only 1 of 13 patients (7.7%) with abdominal wall involvement recurred including both R0 and R1 margin, which is also equivalent to the results of the present study.

Although the postoperative results of abdominal wall desmoid are good, several factors need further consideration. The first is the clinical question of what the surgical margin of abdominal wall desmoid should be. As shown in Table 4, the overall postoperative results are extremely good despite the total of 64 patients of R1 included in the past 6 reports. Combined with the results of the present study, it is suggested that less-invasive, fascia preserving (R1) surgery is acceptable for desmoid arising in the abdominal wall.

Second, as related to the surgical margin, it would be beneficial for patients if reconstruction could be avoided after tumor resection. Sutton et al., Bertani E et al., and Cataniar et al., performed immediate plastic reconstruction (mesh) in all patients after tumor excision. In Bonvalot’s study, 27 (66%) of 41 patients required full-thickness abdominal wall mesh repair. For 17 patients who underwent surgery after AS, mesh was used in all. In our surgical procedure, only two patients required a fascia lata patch, with all of the others avoiding reconstruction.

Third is the clinical question of whether the CTNNB1 variant affects surgical outcomes. In a recent meta-analysis summarizing seven studies, the authors concluded that S45F is a risk factor for local recurrence after surgery compared to T41A, S45P, and WT. On the other hand, no studies focusing on abdominal wall desmoid have been reported. The previous reports shown in Table 4 do not include CTNNB1 data either. However, it is noteworthy that the sole recurrent patient in the present study harbored S45F mutation type.

The fourth is the clinical question of whether background of abdominal wall desmoid (sporadic or FAP-related) affects surgical outcomes. A previous study analyzing the results of surgical treatment for FAP-related desmoid reported that, of 12 abdominal wall desmoids, 8 were completely resected macroscopically, and recurred in 4 patients. This suggests that even with abdominal wall desmoid, the recurrence rate is expected to increase when FAP-related.

Regarding whether the rate of changing to active treatment differs depending on the site of occurrence, Turner et al. found no differences in the risk of progression during AS between abdominal wall tumor and other sites. Another study demonstrated that the 5-year progression free survival of primary cases managed with AS of trunk/thoracic wall tumors and abdominal wall tumors was similar. These results mean that the treatment modality for abdominal desmoid needs to be changed from AS to active treatment at a certain rate.

From the results of the present study, unlike other sites, we recommend less-invasive, fascia preserving surgery rather than systemic treatment as an active treatment for the abdominal wall desmoid. In addition, as shown in Table 3, the high rate of oncological status becoming disease free in the surgery group may be of psychological benefit to patients compared with those in the AS and MTX + VBL groups.

There are several limitations in the present study. The AS cohort included patients treated with meloxicam. However, this is consistent with the systematic review of AS that similarly included studies using non-steroidal anti-inflammatory drugs (NSAIDs). There was no evidence that NSAIDs were effective against desmoid. Although the recurrence rate of abdominal wall desmoid is low, it is still unclear whether CTNNB1 status, especially S45F, is implicated in its recurrence. In the present study, only 15 patients were analyzed, and it is necessary to accumulate more patients in multiple centers to determine whether the recurrence rate is really low with less-invasive and fascia preserving surgery.

Table 4. Studies reporting results of abdominal wall desmoid with surgery. *One case with FAP-related desmoid excluded. **Information for microscopic margin not provided. ***Actual number is unclear. All cohort (147 cases) ratio. NA not available.
Conclusions
For abdominal wall desmoid, less invasive surgery that preserves the fascia has a low recurrence rate and generally does not require reconstruction, despite having an R1 margin. In abdominal wall desmoid, unlike other sites, less invasive surgery might be recommended over systemic treatment when active treatment is required after AS. Further research with an increased number of patients is warranted to verify the significance of this procedure.

Data availability
The research data is available in a data base repository in our institution, and can be available upon reasonable request.

Received: 1 June 2021; Accepted: 15 September 2021
Published online: 29 September 2021

References
1. Kasper, B., Ströbel, P. & Hohenberger, P. Desmoid tumors: Clinical features and treatment options for advanced disease. Oncologist 16, 682–693 (2011).
2. Reitamo, J. J., Hayry, P., Nykyri, E. & Saxen, E. The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. Am. J. Clin. Pathol. 77, 665–673 (1982).
3. Gromich, A. et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: A series of patients surgically treated at a single institution. J. Clin. Oncol. 21, 1390–1397 (2003).
4. Lev, D. et al. Optimizing treatment of desmoid tumors. J. Clin. Oncol. 25, 1785–1791 (2007).
5. Merchant, N. B. et al. Extremity and trunk desmoid tumors: A multifactoral analysis of outcome. Cancer 86, 2045–2052 (1999).
6. Nishida, Y. et al. Risk factors of local recurrence after surgery in extraabdominal desmoid-type fibromatosis: A multicenter study in Japan. Cancer Sci. 111, 2935–2942 (2020).
7. Nishida, Y. et al. Clinical features and treatment outcome of desmoid-type fibromatosis: Based on a bone and soft tissue tumor registry in Japan. Int. J. Clin. Oncol. 24, 1498–1505 (2019).
8. Honeymam, J. et al. Desmoid fibromatosis in children and adolescents: A conservative approach to management. J. Pediatr. Surg. 48, 62–66 (2013).
9. Almen, B. et al. The management of desmoid tumors: A joint global consensus-based guideline approach for adult and paediatric patients. Eur. J. Cancer 127, 96–107 (2020).
10. Fiore, M. et al. Desmoid-type fibromatosis: A front-line conservative approach to select patients for surgical treatment. Ann. Surg. Oncol. 16, 2587–2593 (2009).
11. Crago, A. et al. A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann. Surg. 258, 347–353 (2013).
12. Peng, P. D. et al. Management and recurrence patterns of desmoids tumors: A multi-institutional analysis of 211 patients. Ann. Surg. Oncol. 19, 4036–4042 (2012).
13. Nishida, Y. et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: A wait-and-see policy according to tumor presentation. J. Clin. Oncol. 29, 3553–3558 (2011).
14. Shido, Y. et al. Surgical treatment for local control of extremity and trunk desmoid tumors. Arch. Orthop. Trauma Surg. 129, 929–933 (2009).
15. Bertani, E. et al. Desmoid tumors of the anterior abdominal wall: Results from a monocentric surgical experience and review of the literature. Ann. Surg. Oncol. 16, 1642–1649 (2009).
16. Wilkinson, M. J., Chan, K. E., Hayes, A. J. & Strauss, D. C. Surgical outcomes following resection for sporadic abdominal wall fibromatosis. Ann. Surg. Oncol. 21, 2144–2149 (2014).
17. Kadoch, V. et al. Lattisimus dorsi free flap for reconstruction of extensive full-thickness abdominal wall defect: A case of desmoid tumor. J. Visc. Surg. 147, e45–e48 (2010).
18. Nishida, Y. et al. Simple resection of truncal desmoid tumors: A case series. Oncol. Lett. 12, 1564–1568 (2016).
19. Hamada, S. et al. CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: A pilot study. PLoS ONE 9, e96391 (2014).
20. Nishida, Y. et al. Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: A pilot study. J. Clin. Oncol. 28, e107–e109 (2010).
21. Nishida, Y. et al. Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial. Cancer Sci. 111, 4187–4194 (2020).
22. Palassini, E. et al. Long-term efficacy of meloxicam plus vinblastine/vinorelbine in a large series of patients affected by desmoid-type fibromatosis. Cancer J. 23, 86–91 (2017).
23. Toulmonde, M. et al. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): A non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 20, 1263–1272 (2019).
24. Coloymo, C. et al. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: An independent, multicenter validation study. Cancer 119, 3696–3702 (2013).
25. Lazaro, A. J. et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am. J. Pathol. 173, 1518–1527 (2008).
26. van Broekhoven, D. L. et al. Tailored Beta-catenin mutational approach in extra-abdominal sporadic desmoid tumor patients without therapeutic intervention. BMC Cancer 16, 686 (2016).
27. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
28. Timbergren, M. J. M. et al. Active surveillance in desmoid-type fibromatosis: A systematic literature review. Eur. J. Cancer 137, 18–29 (2020).
29. Bonvalot, S. et al. Spontaneous regression of primary abdominal wall desmoid tumors: More common than previously thought. Ann. Surg. Oncol. 20, 4096–4102 (2013).
30. Catania, G. et al. Abdominal wall reconstruction with intraperitoneal pros thesis in desmoid tumors surgery. Updates Surg. 64, 43–48 (2012).
31. Couto Netto, S. D. et al. Sporadic abdominal wall desmoid type fibromatosis: Treatment paradigm after thirty two years. BMC Surg. 18, 37 (2018).
32. Sutton, R. J. & Thomas, J. M. Desmoid tumours of the anterior abdominal wall. Eur. J. Surg. Oncol. 25, 398–400 (1999).
33. Timbergren, M. J. M. et al. The prognostic role of beta-catenin mutations in desmoid-type fibromatosis undergoing resection only: A meta-analysis of individual patient data. Ann. Surg. https://doi.org/10.1097/SLA.0000000000003698 (2019).
34. Latchford, A. R. et al. A 10-year review of surgery for desmoid disease associated with familial adenomatous polyposis. Br. J. Surg. 93, 1258–1264 (2006).
35. Turner, B. et al. Surgical excision versus observation as initial management of desmoid tumors: A population based study. *Eur. J. Surg. Oncol.* **45**, 699–703 (2019).

**Acknowledgements**

This work was supported in part by the Ministry of Education, Culture, Sports, Science and Technology of Japan [Grant-in-Aid 17H01585 for Scientific Research (A)], the National Cancer Center Research and Development Fund (29-A-3). We thank the patients who participated in our study. We thank Ms. Y. Kawai, Ms. T. Naganuma, Ms. M. Yoshino for secretarial assistance.

**Author contributions**

Conceptualization Y.N.; methodology Y.N., S.H., T.S.; formal analysis Y.N., S.H., K.Ito.; investigation Y.N., S.H., K.Ito.; resources Y.N., T.S., K.Ito., K.Ikuta., H.U., H.K.; data curation Y.N., K.Ito.; writing—original draft preparation Y.N.; writing—review and editing, Y.N., T.S., S.H., K.Ito., K.Ikuta., H.U., H.K., S.I.; project administration Y.N., S.I.; funding acquisition Y.N. All authors have read and agreed to the published version of the manuscript.

**Funding**

This work was supported by in part by the Ministry of Education, Culture, Sports, Science and Technology of Japan [Grant-in-Aid 17H01585 for Scientific Research (A)], the National Cancer Center Research and Development Fund (29-A-3).

**Competing interests**

The authors declare no competing interests.

**Additional information**

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-98775-2.

Correspondence and requests for materials should be addressed to Y.N.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021